Table of Contents
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis

PART 05: MARKET SIZING
• Market definition
• Market sizing 2017
• Market size and forecast

PART 06: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition

PART 07: CUSTOMER LANDSCAPE

PART 08: MARKET SEGMENTATION BY END-USER
• Overview
• Comparison by end-user
• Pharmaceutical and biotechnology companies
• Academic institutes and research laboratories
• Others
• Market opportunity by end-user

PART 09: REGIONAL LANDSCAPE
• Overview
• Regional comparison
• Americas
• EMEA
• APAC
• Market opportunity

PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges

PART 12: MARKET TRENDS
• Growing awareness of microbiome in cancer development and therapy
• Growing demand for highly accurate forensic tools
• Increasing adoption of microbiome sequencing in clinical workflows

PART 13: VENDOR LANDSCAPE
• Overview
• Landscape disruption

PART 14: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• BGI
• Clinical-Microbiomics
• Diversigen
• GATC Biotech
• Second Genome
• Other prominent vendors

PART 15: APPENDIX
• List of abbreviations

[List of Exhibits]
Exhibit 01: Related market
Exhibit 02: Market characteristics
Exhibit 03: Market segments
Exhibit 04: Market definition – Inclusions and exclusions checklist
Exhibit 05: Market size 2017
Exhibit 06: Validation techniques employed for market sizing 2017
Exhibit 07: Global microbiome sequencing services market – Market size and forecast 2017-2022 ($ mn)
Exhibit 08: Global microbiome sequencing services market – Year over year growth 2018-2022 (%)
Exhibit 09: Five forces analysis 2017
Exhibit 10: Five forces analysis 2022
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition – Five forces 2017
Exhibit 17: Market condition: Five forces 2022
Exhibit 18: Customer landscape
Exhibit 19: End-user – Market share 2017-2022 (%)
Exhibit 20: Comparison by end-user
Exhibit 21: Pharmaceutical and biotechnology companies – Market size and forecast 2017-2022 ($ mn)
Exhibit 22: Pharmaceutical and biotechnology companies – Year over year growth 2018-2022 (%)
Exhibit 23: Academic institutes and research laboratories – Market size and forecast 2017-2022 ($ mn)
Exhibit 24: Academic institutes and research laboratories – Year over year growth 2018-2022 (%)
Exhibit 25: Others – Market size and forecast 2017-2022 ($ mn)
Exhibit 26: Others – Year over year growth 2018-2022 (%)
Exhibit 27: Market opportunity by end-user
Exhibit 28: Global – Market share by geography 2017-2022 (%)
Exhibit 29: Regional comparison
Exhibit 30: Americas – Market size and forecast 2017-2022 ($ mn)
Exhibit 31: Americas – Year over year growth 2018-2022 (%)
Exhibit 32: Top 3 countries in Americas
Exhibit 33: EMEA – Market size and forecast 2017-2022 ($ mn)
Exhibit 34: EMEA – Year over year growth 2018-2022 (%)
Exhibit 35: Top 3 countries in EMEA
Exhibit 36: APAC – Market size and forecast 2017-2022 ($ mn)
Exhibit 37: APAC – Year over year growth 2018-2022 (%)
Exhibit 38: Top 3 countries in APAC
Exhibit 39: Market opportunity
Exhibit 40: R&D funding in $ millions for malaria from 2013-2016
Exhibit 41: R&D funding in $ millions for HIV from 2013-2016
Exhibit 42: Cost of sequencing per genome in $ (2001-2015)
Exhibit 43: Vendor landscape
Exhibit 44: Landscape disruption
Exhibit 45: Vendors covered
Exhibit 46: Vendor classification
Exhibit 47: Market positioning of vendors
Exhibit 48: BGI: Overview
Exhibit 49: BGI: Business segments
Exhibit 50: BGI: Organizational developments
Exhibit 51: BGI: Geographic focus
Exhibit 52: BGI: Segment focus
Exhibit 53: BGI: Key offerings
Exhibit 54: Clinical-Microbiomics: Overview
Exhibit 55: Clinical-Microbiomics: Business segments
Exhibit 56: Clinical-Microbiomics: Organizational developments
Exhibit 58: Clinical-Microbiomics: Geographic focus
Exhibit 59: Clinical-Microbiomics: Segment focus
Exhibit 60: Clinical-Microbiomics: Key offerings
Exhibit 61: Diversigen: Overview
Exhibit 62: Diversigen – Business segments
Exhibit 63: Diversigen – Organizational developments
Exhibit 64: Diversigen – Geographic focus
Exhibit 65: Diversigen – Segment focus
Exhibit 66: Diversigen – Key offerings
Exhibit 67: GATC Biotech: Overview
Exhibit 68: GATC Biotech: Business segments
Exhibit 69: GATC Biotech: Organizational developments
Exhibit 70: GATC Biotech: Geographic focus
Exhibit 71: GATC Biotech: Segment focus
Exhibit 72: GATC Biotech – Key offerings
Exhibit 73: Second Genome: Overview
Exhibit 74: Second Genome – Business segments
Exhibit 75: Second Genome – Organizational developments
Exhibit 76: Second Genome – Geographic focus
Exhibit 77: Second Genome – Segment focus
Exhibit 78: Second Genome – Key offering